EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis

Ioana Agache, Cezmi A. Akdis, Mubeccel Akdis, Knut Brockow, Tomas Chivato, Stefano del Giacco, Thomas Eiwegger, Kilian Eyerich, Ana Giménez-Arnau, Jan Gutermuth, Emma Guttman-Yassky, Marcus Maurer, Graham Ogg, Peck Y. Ong, Liam O’Mahony, Jürgen Schwarze, Amena Warner, Thomas Werfel, Oscar Palomares, Marek JutelRiccardo Asero, Marta Ferrer Puga, Ignasi Figueras Nart, Massimo Gadina, Kenji Kabashima, Kazunari Sugita

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based), its cost-effectiveness and long-term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed.

Original languageEnglish
Pages (from-to)988-1009
Number of pages22
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume76
Issue number4
DOIs
StatePublished - Apr 2021

Keywords

  • GRADE
  • atopic dermatitis
  • dupilumab
  • guideline

Fingerprint

Dive into the research topics of 'EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis'. Together they form a unique fingerprint.

Cite this